Complement factor D-IN-1
目录号 : GC31846
ComplementfactorD-IN-1是一种有效的和选择性的小分子可逆因子(small-moleculereversiblefactord)抑制剂，在FD硫酯分解荧光实验和MAC沉积测定中IC50值分别为0.006和0.05μM。
Cas No.:1386455-76-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.
The highly specific S1 serine protease factor D (FD) plays a central role in the amplification of the complement alternative pathway (AP) of the innate immune system. Complement factor D-IN-1 (compound 2) shows similar potency against human and monkey FD (IC50s in FD thioesterolytic assays of 0.005 μM and in 50% serum MAC deposition assays of 0.011 μM for both human and monkey)[1].
Complement factor D-IN-1 displays an excellent oral PK profile in Sprague-Dawley rats and, following an oral dose (10 mg/kg) in Brown Norway rats, demonstrates a good distribution and sustained exposure in ocular tissues including the neural retina and the posterior eye cup (PEC), which comprises the sclera, retinal pigmented epithelium, and choroid. Mean exposure levels in plasma, the PEC, and the retina at 6 h after dosing are 0.36, 0.43, and 0.09 μM, respectively[1].
[1]. Lorthiois E, et al. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D InhibitorsDemonstrating Alternative Complement Pathway Inhibition in Vivo. J Med Chem. 2017 Jul 13;60(13):5717-5735.
Animal experiment: | Mice[1]Complement factor D-IN-1 is tested at 30 mg/kg in the human factor D knock-in mouse pharmacodynamic model. Groups of mice (n=4, female human FD knock-in) are treated either with Complement factor D-IN-1 or dosing vehicle by oral gavage at 24, 16, 12, 8, 6, and 4 h, respectively, prior to the termination of the study. All animals are given intraperitoneal LPS to activate complement 7.5 h prior to study termination. Baseline complement levels are obtained from mice that received oral dosing vehicle and intraperitoneal saline (indicated by PBS line on graph). The positive control group receives oral dosing vehicle and intraperitoneal LPS[1]. |
References: [1]. Lorthiois E, et al. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D InhibitorsDemonstrating Alternative Complement Pathway Inhibition in Vivo. J Med Chem. 2017 Jul 13;60(13):5717-5735. | |
| Cas No. | 1386455-76-0 | SDF | |
| Canonical SMILES | O=C(N)C1=NN(CC(N2[C@H](C(NC3=CC=CC(Br)=N3)=O)C[C@@H]4[C@H]2C4)=O)C5=C1C=CC=C5 | ||
| 分子式 | C21H19BrN6O3 | 分子量 | 483.32 |
| 溶解度 | DMSO: 250 mg/mL (517.26 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.069 mL | 10.3451 mL | 20.6902 mL |
| 5 mM | 0.4138 mL | 2.069 mL | 4.138 mL |
| 10 mM | 0.2069 mL | 1.0345 mL | 2.069 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet